Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
2. Darifenacin
3. Darifenacin Hydrochloride
4. Darifenacine
5. Darifenicin
6. Emselex
7. Enablex
8. Uk-88525
1. Darifenacin Hbr
2. 133099-07-7
3. Emselex
4. Darifenacin (hydrobromide)
5. Darifenacin Hydrobromide [usan]
6. Cr02eyq8gv
7. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide
8. Uk-88525-04 (hydrobromide)
9. Chebi:31455
10. Uk-88525-04 (hbr)
11. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide Hydrobromide
12. 133099-07-7 (hbr)
13. Dsstox_cid_26780
14. Dsstox_rid_81899
15. Dsstox_gsid_46780
16. (s)-2-{1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide Hydrobromide
17. Uk-88525
18. Darilong
19. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
20. Uk 88525-04 Hydrobromide
21. Cas-133099-07-7
22. Ncgc00168775-01
23. Unii-cr02eyq8gv
24. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hydrobromide
25. 2-{(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide Hydrobromide
26. Enablex (tn)
27. Darifenacinhydrobromide
28. Diphenyl-acetamide Hydrobromide
29. Darifenacin Hydrobromide- Bio-x
30. Chembl1200935
31. Dtxsid9046780
32. Hy-a0012
33. Tox21_112636
34. Darifenacin Hydrobromide (jan/usan)
35. Darifenacin Hydrobromide [mi]
36. Mfcd08141803
37. S3144
38. Darifenacin Hydrobromide [jan]
39. Akos015969311
40. Tox21_112636_1
41. Ac-1894
42. Ccg-220969
43. Cs-0380
44. Darifenacin Hydrobromide [mart.]
45. Darifenacin Hydrobromide [usp-rs]
46. Darifenacin Hydrobromide [who-dd]
47. Ncgc00263922-02
48. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (3s)-
49. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (s)-
50. 3-pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-alpha,alpha-diphenyl-, Hydrobromide (1:1), (3s)-
51. As-35087
52. Bd164350
53. Darifenacin Hydrobromide [ema Epar]
54. Darifenacin Hydrobromide, >=98% (hplc)
55. Sw219426-1
56. Darifenacin Hydrobromide [orange Book]
57. Uk-88525-04
58. D01699
59. Q-101006
60. Q27114313
61. Z1691545283
62. Darifenacin Hydrobromide, United States Pharmacopeia (usp) Reference Standard
63. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hbr
64. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohbr, (3s)-
65. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohydrobromide, (3s)-
Molecular Weight | 507.5 g/mol |
---|---|
Molecular Formula | C28H31BrN2O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 506.15689 g/mol |
Monoisotopic Mass | 506.15689 g/mol |
Topological Polar Surface Area | 55.6 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 607 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
2 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
3 of 4 | |
---|---|
Drug Name | Darifenacin hydrobromide |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | oral |
Strength | 7.5mg; 15mg |
Market Status | Tentative Approval |
Company | Anchen Pharms |
4 of 4 | |
---|---|
Drug Name | Enablex |
PubMed Health | Darifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
Active Ingredient | Darifenacin hydrobromide |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 15mg base; eq 7.5mg base |
Market Status | Prescription |
Company | Warner Chilcott |
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04BD10
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
34
PharmaCompass offers a list of Darifenacin Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Darifenacin Hydrobromide manufacturer or Darifenacin Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Darifenacin Hydrobromide manufacturer or Darifenacin Hydrobromide supplier.
PharmaCompass also assists you with knowing the Darifenacin Hydrobromide API Price utilized in the formulation of products. Darifenacin Hydrobromide API Price is not always fixed or binding as the Darifenacin Hydrobromide Price is obtained through a variety of data sources. The Darifenacin Hydrobromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A UK-88525 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of UK-88525, including repackagers and relabelers. The FDA regulates UK-88525 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. UK-88525 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of UK-88525 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A UK-88525 supplier is an individual or a company that provides UK-88525 active pharmaceutical ingredient (API) or UK-88525 finished formulations upon request. The UK-88525 suppliers may include UK-88525 API manufacturers, exporters, distributors and traders.
click here to find a list of UK-88525 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A UK-88525 DMF (Drug Master File) is a document detailing the whole manufacturing process of UK-88525 active pharmaceutical ingredient (API) in detail. Different forms of UK-88525 DMFs exist exist since differing nations have different regulations, such as UK-88525 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A UK-88525 DMF submitted to regulatory agencies in the US is known as a USDMF. UK-88525 USDMF includes data on UK-88525's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The UK-88525 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of UK-88525 suppliers with USDMF on PharmaCompass.
A UK-88525 written confirmation (UK-88525 WC) is an official document issued by a regulatory agency to a UK-88525 manufacturer, verifying that the manufacturing facility of a UK-88525 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting UK-88525 APIs or UK-88525 finished pharmaceutical products to another nation, regulatory agencies frequently require a UK-88525 WC (written confirmation) as part of the regulatory process.
click here to find a list of UK-88525 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing UK-88525 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for UK-88525 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture UK-88525 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain UK-88525 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a UK-88525 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of UK-88525 suppliers with NDC on PharmaCompass.
UK-88525 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of UK-88525 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right UK-88525 GMP manufacturer or UK-88525 GMP API supplier for your needs.
A UK-88525 CoA (Certificate of Analysis) is a formal document that attests to UK-88525's compliance with UK-88525 specifications and serves as a tool for batch-level quality control.
UK-88525 CoA mostly includes findings from lab analyses of a specific batch. For each UK-88525 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
UK-88525 may be tested according to a variety of international standards, such as European Pharmacopoeia (UK-88525 EP), UK-88525 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (UK-88525 USP).